HealthDay on MSN17h
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate Cancer
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
Targeted Oncology9h
Therapeutic options for a patient with mCRPC after ADT + docetaxel
An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...
Cancer Stocks Enter A Defining Year As Innovation Surges In 2025
New Diagnostics, AI Breakthroughs, and Next-Gen Therapies Are Transforming the Oncology Market. The oncology sector is experiencing <stron ...